📰 Study Director News
Study Director News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Study Director. Real-time updates on events, politics, business and more.
January 30, 2024
On Jan. 25, DoD announced that Lockheed Martin and Boeing have each won 15-month contracts worth $66 million to develop a new, more modern satellite design, with the service then deciding on which to use in building the two new MUOS birds.
September 21, 2023
LAVAL, Québec--(BUSINESS WIRE)--#Altasciences--Altasciences is pleased to have been chosen by Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) (“Virpax”), a company specializing in developing non-addictive products for pain management, PTSD, central nervous system (CNS) disorders, and viral barrier indications, to conduct...
September 13, 2023
In the rapidly evolving world of pharmaceutical development, high-potency active pharmaceutical ingredients (HPAPIs) are becoming powerful tools.
May 2, 2023
Explore human FcRn mouse models that provide accurate preclinical assessment to give translational pharmacokinetic data
March 4, 2023
Dr. Lisette M. Garcia is coming back to the organization as Chief Research Officer.
February 20, 2023
Researchers from the University of Washington (UW), Kenya Medical Research Institute (KEMRI), and Hennepin Healthcare Research Institute (HHRI) announced results at CROI from a clinical trial demonstrating that doxycycline taken after sex does not prevent bacterial sexually transmitted infections (STIs) – chlamydia or gonorrhea – among cisgender women.
February 13, 2023
Toronto, ON (PRWEB) February 13, 2023 -- Join this webinar to hear the featured speakers address global clinical sample challenges, with a focus on logistical
June 21, 2022
GuruFocus Article or News written by PRNewswire and the topic is about:
May 17, 2022
Forge Biologics Forms Independent Scientific and Manufacturing Advisory Board with Panel of Gene Therapy Leaders - read this article along with other careers information, tips and advice on BioSpace
May 15, 2022
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced two...